Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinobiomed has applied for a new Chinese and an international patent for recombinant human kallikrein-1 and for a Chinese patent for a recombinant multivalent tuberculosis vaccine.
Subscribe to our email newsletter
The company has submitted its international patent application for recombinant human kallikrein-1 to the Patent Cooperation Treaty. It has also applied to China’s State Intellectual Property Office (SIPO) for a Chinese patent for the aqueous formulation for injection.
The company has submitted its application to SIPO for a Chinese patent for the multivalent tuberculosis.
Recombinant human kallikrein-1 is a product Sinobiomed is developing for the treatment of stroke and peripheral vascular disorders, and for the prevention of blood clots and thrombosis.